Drugs / M-FLUOROBENZYLGUANIDINE
M-FLUOROBENZYLGUANIDINE
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT05069220 | Sep 2021 → Sep 2025 overdue | neuroblastoma, paraganglioma, pheochromocytoma | Peking Union Medical College Hospital | Recruiting | No outcome recorded |
| Phase 11 trial | ||||||
| Phase 1 | NCT04258592 | Feb 2020 → Jul 2022 | neurocristopathy, neuroendocrine neoplasm | Universitaire Ziekenhuizen KU Leuven | Terminated | No outcome recorded Stop: Enrollment |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT04535193 | Nov 2021 → Mar 2025 overdue | cardiovascular disorder | Innervate Radiopharmaceuticals LLC | Active not recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT06233903 | Jan → Sep 2025 | neuroblastoma, paraganglioma, pheochromocytoma | Innervate Radiopharmaceuticals LLC | Withdrawn | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT04724369 | Nov 2021 → Jul 2026 | neuroblastoma | Innervate Radiopharmaceuticals LLC | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT07176286 Comparator | Apr → Oct 2026 expected | Lewy body dementia, Parkinson disease | Innervate Radiopharmaceuticals LLC | Recruiting | No outcome recorded |
Evidence & citations 12 cited values
Every value below carries the sentence it was read from. 8 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | M-FLUOROBENZYLGUANIDINE | ChEMBL registry synonym — accepted as the source's own label CHEMBL111272 ↗ |
| Known as | [18F]-meta-fluorobenzylguanidine | “This study uses 18F-meta-fluorobenzylguanidine (18F-mFBG), a new radiopharmaceutical similar in structure to 123I-mIBG but with faster pharmacokinetics and elimination.” NCT07176286 ↗1“PURPOSE: [18F]-meta-fluorobenzylguanidine ([18F]MFBG) and somatostatin receptor (SSTR)-targeted PET tracers have both been proposed for imaging neuroblastoma” PMID 40717185 ↗ Jul 2025 |
| Known as | [18F]-MFBG | “This study uses 18F-meta-fluorobenzylguanidine (18F-mFBG), a new radiopharmaceutical similar in structure to 123I-mIBG but with faster pharmacokinetics and elimination.” NCT07176286 ↗7“PURPOSE: [18F]-meta-fluorobenzylguanidine ([18F]MFBG) and somatostatin receptor (SSTR)-targeted PET tracers have both been proposed for imaging neuroblastoma” PMID 40717185 ↗ Jul 2025 |
| Known as | Florbenguane (18f) | ChEMBL registry synonym — accepted as the source's own label CHEMBL111272 ↗ |
| Known as | FLORBENGUANE F18 | ChEMBL registry synonym — accepted as the source's own label CHEMBL111272 ↗ |
| Known as | Florbenguano (18f) | ChEMBL registry synonym — accepted as the source's own label CHEMBL111272 ↗ |
| Known as | IRP101 | “Other Names: * meta-fluorobenzylguanidine * IRP101” NCT04724369 ↗ |
| Known as | M-(18f)-fluorobenzylguanidine | ChEMBL registry synonym — accepted as the source's own label CHEMBL111272 ↗ |
| Known as | meta-fluorobenzylguanidine | “Other Names: * meta-fluorobenzylguanidine * IRP101” NCT04724369 ↗ |
| Known as | Mfbg f-18 | ChEMBL registry synonym — accepted as the source's own label CHEMBL111272 ↗ |
| Modality | Diagnostic / imaging agent | “18F-mFBG as an imaging agent” NCT04535193 ↗ |
| Route | Intravenous | “18F-MFBG will be intravenously injected” NCT04258592 ↗ |